Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma.

ABSTRACT: Multiple myeloma is a prevalent and incurable disease, despite the development of new and effective drugs. The recent development of chimeric antigen receptor (CAR)-T cell therapy has shown impressive results in the treatment of patients with relapsed or refractory hematological B cell malignancies. In the recent years, B-cell maturation antigen (BCMA) has appeared as a promising antigen to target using a variety of immuno-therapy treatments including CART cells, for MM patients. To this end, we generated clinical-grade murine CART cells directed against BCMA, named ARI2m cells. Having demonstrated its efficacy, and in an attempt to avoid the immune rejection of CART cells by the patient, the single chain variable fragment was humanized, creating ARI2h cells. ARI2h cells demonstrated compa

SUBMITTER: Perez-Amill L 

PROVIDER: S-EPMC7776337 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature